JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Subscribe To Our Newsletter & Stay Updated